Virus associated hemophagocytic syndrome (VAHS)
Not for Routine Use
When screening requests for approval, the following information may be taken into account as there is some evidence for IG to be considered as an option.
Order Number: H20-VAHS
| Recommendations | IVIG is not recommended for routine use in the treatment of VAHS. IVIG may be considered among the options for treatment of severe life threatening VAHS. |
| Dose/Frequency of Administration | No recommended dose or duration listed; however, expert panel recommends up to 2 g/kg divided over 2 to 5 consecutive days |